Page last updated: 2024-11-12
malbrancheamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
malbrancheamide: from the culture medium and mycelia of the ascomycete Malbranchea aurantiaca; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11553183 |
| CHEMBL ID | 508749 |
| SCHEMBL ID | 9942106 |
| MeSH ID | M0522067 |
Synonyms (8)
| Synonym |
|---|
| CHEMBL508749 , |
| (+)-malbrancheamide |
| SCHEMBL9942106 |
| malbrancheamide |
| (1s,13s,15s)-6,7-dichloro-12,12-dimethyl-10,19,21-triazahexacyclo[13.5.2.01,13.03,11.04,9.015,19]docosa-3(11),4,6,8-tetraen-22-one |
| (5as,12as,13as)-8,9-dichloro-12,12-dimethyl-2,3,11,12,12a,13-hexahydro-1h,5h,6h-5a,13a-(epiminomethano)indolizino[7,6-b]carbazol-14-one |
| J6P , |
| bdbm50540272 |
Research Excerpts
Overview
Malbrancheamide is a dichlorinated fungal indole alkaloid isolated from Malbranchea aurantiaca. It belongs to a family of natural products containing a characteristic bicyclo[2.2]diazaoctane core.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Malbrancheamide is a dichlorinated fungal indole alkaloid isolated from both Malbranchea aurantiaca and Malbranchea graminicola that belongs to a family of natural products containing a characteristic bicyclo[2.2.2]diazaoctane core. " | ( Function and Structure of MalA/MalA', Iterative Halogenases for Late-Stage C-H Functionalization of Indole Alkaloids. Crews, P; Dan, Q; Fraley, AE; Garcia-Borràs, M; Houk, KN; Khare, D; Mercado-Marin, EV; Sarpong, R; Sherman, DH; Smith, JL; Tran, H; Tripathi, A; Watts, KR; Webb, GP; Williams, RM, 2017) | 1.9 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | IC50 (µMol) | 14.5000 | 0.0005 | 3.4984 | 9.7600 | AID1654053 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (27)
Molecular Functions (12)
Ceullar Components (11)
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1654051 | Inhibition of rat intestinal rat alpha-glucosidase | |||
| AID411091 | Ratio of IC50 of chlorpromazine to IC50 of compound for bovine brain PDE1 | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 | Calmodulin inhibitory activity of the malbrancheamides and various analogs. |
| AID411090 | Inhibition of bovine brain PDE1 | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 | Calmodulin inhibitory activity of the malbrancheamides and various analogs. |
| AID1654052 | Induction of hypo glycemic activity in ICR mouse assessed as reduction in postprandial glucose level at 10 mg/kg, po pretreated for 30 mins followed by sucrose treatment and measured after 30 to 120 mins | |||
| AID1654050 | Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate preincubated for 10 mins followed by substrate addition after 20 mins | |||
| AID1654053 | Inhibition of human PTP1B expressed in Escherichia coli BL21 (DE3) cells using PNPP as substate preincubated for 5 mins followed by substrate additon and measured after 15 mins | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.14
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.14) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||